Walgreens Boots Alliance Inc. (WBA) analysts have stopped believing.
The most recent downgrade came from Mizuho analyst Ann Hynes. She slashed Walgreens to neutral from buy on Monday, July 2, and her price target on the stock to $64 from $77.
Walgreens rose 1.5% on Monday to $60.90.
Lee reported last week that RBC analyst George Hill said the diversified assets of the pending CVS-Aetna Inc. (AET) combination "on a pro forma basis should enable CVS to better weather the risk that Amazon is able to grab pharmacy market share versus WBA." CVS in December agreed to acquire Aetna for $69 billion.
Hill lowered his price target on CVS to $84 from $91 on the heels of Amazon's PillPack deal, but said it won't be easy for Amazon to squeeze pharmacy margins in the near- to medium-term. He pointed to factors such as the "the stickiness of payer/pharmacy relationships, decreasing share of mail order, and PillPack's tiny market share."
CVS shares rose 0.2% to $64.47.